Download Anesthesia for Congenital Heart Disease, Second Edition PDF

TitleAnesthesia for Congenital Heart Disease, Second Edition
Author
LanguageEnglish
File Size13.8 MB
Total Pages674
Table of Contents
                            Anesthesia for
Congenital Heart Disease
	Contents
	List of Contributors
	Preface
	Acknowledgements
	Part 1: History, Education, Outcomes, and Science
		Chapter 1: History of Anesthesia for Congenital Heart Disease
		Chapter 2: Education for Anesthesia in Patients with Congenital Cardiac Disease
		Chapter 3: Quality, Outcomes, and Databases in Congenital Cardiac Anesthesia
		Chapter 4: Embryology, Development, and Nomenclature of Congenital Heart Disease
		Chapter 5: Physiology and Molecular Biology of the Developing Circulation
		Chapter 6: Anesthetic Agents and Their Cardiovascular Effects
		Chapter 7: Cardiopulmonary Bypass
		Chapter 8: The Inflammatory Response and Its Modification
	Part 2: Monitoring
		Chapter 9: Vascular Access and Monitoring
		Chapter 10: Neurologic Monitoring and Outcome
		Chapter 11: Transesophageal Echocardiography Congenital Heart Disease
		Chapter 12: Bleeding and Coagulation: Monitoring and Management
	Part 3: Preoperative Considerations
		Chapter 13: Preoperative Evaluation and Preparation
		Chapter 14: Approach to the Fetus, Premature, and Full-Term Infant
		Chapter 15: Approach to the Teenaged and Adult Patient
	Part 4: Management,
		Chapter 16: Hemodynamic Management
		Chapter 17: Arrhythmias: Diagnosis and Management
		Chapter 18: Airway and Ventilatory Management
		Chapter 19: Regional Anesthesia and Postoperative Pain Management
	Part 5: Anesthesia for Specific Lesions
		Chapter 20: Anesthesia for Left-to-Right Shunt Lesions
		Chapter 21: Anesthesia for Left-Sided Obstructive Lesions
		Chapter 22: Anesthesia for Right-Sided Obstructive Lesions
		Chapter 23: Anesthesia for Transposition of the Great Vessels
		Chapter 24: Anesthesia for the Patient with a Single Ventricle
		Chapter 25: Anesthesia for Miscellaneous Cardiac Lesions
		Chapter 26: Anesthesia for Cardiac and Pulmonary Transplantation
	Part 6: Anesthesia Outside the Cardiac Operating Room
		Chapter 27: Anesthesia for the Cardiac Catheterization Laboratory
		Chapter 28: Anesthesia for Noncardiac Surgery and Magnetic Resonance Imaging
		Chapter 29: Cardiac Intensive Care
		Chapter 30: Mechanical Support of the Circulation
	Appendix : Texas Children’s Hospital Pediatric Cardiovascular Anesthesia Drug Sheet (March 2009)
	Index
	Color Plates
                        
Document Text Contents
Page 337

c16 BLBK212-Andropoulos Trim: 216mm × 279mm October 29, 2009 17:17 Char Count=

CHAPTER 16 Hemodynamic management

28. Mehra M, Ventura H, Kapoor C, et al. (1997) Safety and clin-
ical utility of long term intravenous milrinone in advanced
heart failure. Am J Cardiol 80:61–64.

29. Edelson J (1986) Pharmocokinetics of bipyridines amrinone
and milrinone. Circulation 73:145–155.

30. Hoffman TM, Wernovsky G, Atz AM, et al. (2003) Efficacy
and safety of milrinone in preventing low cardiac output
syndrome in infants and children after corrective surgery
for congenital heart disease. Circulation 107:996–1002.

31. Zuppa AF, Nicolson SC, Adamson PC, et al. (2006) Popu-
lation pharmacokinetics of milrinone in neonates with hy-
poplastic left heart syndrome undergoing stage I reconstruc-
tion. Anesth Analg 102:1062–1069.

32. Drop L, Geffin G, O’Keefe D, et al. (1981) Relation between
ionized calcium concentration and ventricular pump perfor-
mance in the dog under hemodynamically controlled con-
ditions. Am J Cardiol 47:1041–1051.

33. Robertie P, Butterworth J, Royster R, et al. (1991) Normal
parathyroid hormone responses to hypocalcemia during
cardiopulmonary bypass. Anesthesiology 75:43–48.

34. Elz J, Panagiotopoulos S, Nayker W, et al. (1989) Reper-
fusion induced calcium gain after ischemia. Am J Cardiol
63:7E–13E.

35. Royster R, Butterworth J, Prielipp R, et al. (1992) A random-
ized blinded, placebo-controlled evaluation of calcium chlo-
ride and epinephrine for inotropic support after emergence
from cardiopulmonary bypass. Anesth Analg 74:3–13.

36. Murdoch I, Qureshi S, Huggon I (1983) Perioperative hemo-
dynamic effects of an intravenous infusion of calcium chlo-
ride in children following cardiac surgery. Acta Paediatr
83:658–661.

37. Broner CW, Stidham GL, Westenkirchner DF, Watson DC
(1990) A prospective, randomized, double-blind compari-
son of calcium chloride and calcium gluconate therapies for
hypocalcemia in critically ill children. J Pediatr 117:986–989.

38. Dyke PC, Yates AR, Cua CL, et al. (2007) Increased calcium
supplementation is associated with morbidity and mortality
in the infant postoperative cardiac patient. Pediatr Crit Care
Med 8:254–257.

39. Walters P, Cooper T, Denison A, et al. (1955) Dilator re-
sponses to isoproterenol in cutaneous and skeletal muscle
vascular beds of adrenergic blocking drugs. J Pharmacol Exp
Ther 115:323–327.

40. Vatner S, Baig H (1978) Comparison of the effects of ouabain
and isoproterenol on ischemic myocardium of conscious
dogs. Circulation 58:654–662.

41. Clutter W, Bier D, Shah S, et al. (1980) Epinephrine plasma
metabolic clearance rates and physiologic thresholds for
metabolic and hemodynamic actions in man. J Clin Invest
66:94–101.

42. Tourneux P, Rakza T, Abazine A, et al. (2008) Noradrenaline
for management of septic shock refractory to fluid loading
and dopamine or dobutamine in full-term newborn infants.
Acta Paediatr 97:177–180.

43. Oshita S, Uchimoto R, Oka H, et al. (1989) Correlation be-
tween arterial blood pressure and oxygenation in Tetralogy
of Fallot. J Cardiothorac Anesth 3:597–600.

44. Stewart WJ, Schiavone WA, Salcedo EE, et al. (1987) Interper-
ative Doppler echocardiography in hypertrphic cardiomy-

opathy: correlations with the obstructive gradient. J Am Coll
Cardiol 10:327–335.

45. Holmes CL, Patel BM, Russell JA, et al. (2001) Physiology of
vasopressin relevant to management of septic shock. Chest
120:989–1002.

46. Rosenzweig E, Starc T, Chen J, et al. (1999) Intravenous
arginine-vasopressin in children with vasodilatory shock
after cardiac surgery. Circulation 9 (100):182–186.

47. O’Blenes SB, Roy N, Konstantinov I, et al. (2002) Vaso-
pressin reversal of phenoxybenzamine-induced hypoten-
sion after the Norwood procedure. J Thorac Cardiovasc Surg
123:1012–1013.

48. Strauer B, Scherpe A (1978) Ventricular function and coro-
nary hemodynamics after intravenous nitroglycerin in coro-
nary artery disease. Am Heart J 95:210–219.

49. Ilbawi M, Farouk I, Serafin D, et al. (1985) Hemodynamic
effects of intravenous nitroglycerin in pediatric patients after
heart surgery. Circulation 72 (II):101–107.

50. Gibson G, Hunter J, Rabe D, et al. (1982) Methemoglobine-
mia produced by high dose nitroglycerin. Ann Intern Med
96:615–616.

51. Benitz WE, Malachowski N, Cohen RS, et al. (1985) Use
of sodium nitroprusside in neonates: efficacy and safety. J
Pediatr 106:102–110.

52. Moffett BS, Price JF (2008) Evaluation of sodium nitroprus-
side toxicity in pediatric cardiac surgical patients. Ann Phar-
macother 42:1600–1604.

53. Tabbutt S, Nicolson SC, Adamson PC, et al. (2008) The safety,
efficacy, and pharmacokinetics of esmolol for blood pressure
control immediately after repair of coarctation of the aorta in
infants and children: a multicenter, double-blind, random-
ized trial. J Thorac Cardiovasc Surg 136:321–328.

54. Ohara T, Ogata H, Fujiyama J, et al. (1985) Effects of
prostaglandin E1 infusion in the pre-operative management
of critical congenital heart disease. Tohoku J Exp Med 146
(2):237–249.

55. Freed M, Heyman M, Rudolph A, et al. (1981) Prostaglandin
E1 in ductus arteriosus dependent congenital heart disease.
Circulation 64:889–905.

56. D’Ambra M, LaRaia P, Philbin D, et al. (1985) Prostaglandin
E1: a new therapy for refractory right heart failure and pul-
monary hypertension after mitral valve replacement. J Tho-
rac Cardiovasc Surg 89:567–572.

57. Rubis L, Stephenson L, Johnston M, et al. (1981) Compar-
ison of effects of prostaglandin E1 and nitroprusside on
pulmonary vascular resistance in children after open-heart
surgery. Ann Thorac Surg 32 (6):563–570.

58. Armitage J, Hardesty R, Griffith B, et al. (1987) Prostaglandin
E1: an effective treatment of right heart failure after ortho-
topic heart transplantation. J Heart Transplant 6:348–351.

59. Kermode J, Butt W, Shann F (1991) Comparison between
prostaglandin E1 and epoprostenol in infants after heart
surgery. Br Heart J 66:175–178.

60. Schulze-Neick I, Uhlemann F, Nurnberg J, et al. (1997)
Aerosolized prostacyclin for preoperative evaluation and
post-cardiosurgical treatment of patients with pulmonary
hypertension. Z Kardiol 86:71–80.

61. Haraldsson A, Kieler J, Ricksten S (1996) Inhaled prosta-
cyclin for the treatment of pulmonary hypertension after

305

Page 338

c16 BLBK212-Andropoulos Trim: 216mm × 279mm October 29, 2009 17:17 Char Count=

PART 4 Management

cardiac surgery or heart transplantation: a pharmacody-
namic study. J Cardiothorac Vasc Anesth 10:864–868.

62. Zwissler B, Kemming G, Habler O, et al. (1996) Inhaled
prostacyclin (PGI2) versus inhaled nitric oxide in adult res-
piratory distress syndrome. Am J Respir Crit Care Med
154:1671–1677.

63. Müller M, Scholz S, Kwapisz M, et al. (2003) Use of in-
haled iloprost in a case of pulmonary hypertension during
pediatric congenital heart surgery. Anesthesiology 99:743–
744.

64. Shekerdemian LS, Ravn HB, Penny DJ (2002) Intravenous
sildenafil lowers pulmonary vascular resistance in a model
of neonatal pulmonary hypertension. Am J Respir Crit Care
Med 165:1098–1102.

65. Atz AM, Wessel DL (1999) Sildenafil ameliorates ef-
fects of inhaled nitric oxide withdrawal. Anesthesiology
91:307–310.

66. Raja SG, Danton MD, MacArthur KJ, Pollock JC (2007) Ef-
fects of escalating doses of sildenafil on hemodynamics
and gas exchange in children with pulmonary hypertension
and congenital cardiac defects. J Cardiothorac Vasc Anesth
21:203–207.

67. Roberts J, Lang P, Bigatello L, et al. (1993) Inhaled nitric
oxide in congenital heart disease. Circulation 87:447–453.

68. Miller O, Celermeyer D, Deanfield J, et al. (1994) Very low
dose inhaled nitric oxide: a selective pulmonary vasodila-
tor after operations for congenital heart disease. J Thorac
Cardiovasc Surg 108:487–494.

69. Kieler-Jensen N, Lundin S, Ricksten S (1995) Vasodilator
therapy after heart transplantation: effects of inhaled ni-
tric oxide and intravenous prostacyclin, prostaglansin E1
sodium nitroprusside. J Heart Lung Transplant 14:436–443.

70. Turanlahti M, Laitinen P, Pesonen E (2000) Preoperative and
postoperative response to inhaled nitric oxide. Scand Car-
diovasc J 34:46–52.

71. Kadosaki M, Kawamura T, Oyama K, et al. (2002) Usefulness
of nitric oxide treatment for pulmonary hypertensive infants
during cardiac anesthesia. Anesthesiology 96:835–840.

72. Winberg P. Lundell B, Gustafsson L (1994) Effects of inhaled
nitric oxide on raised pulmonary vascular resistance in chil-
dren with congenital heart disease. Br Heart J 71:282–286.

73. Sadao K, Masahiro S, Toshihiko M, et al. (1997) Effect of
nitric oxide on oxygenation and hemodynamics in infants
after cardiac surgery. Artif Organs 21 (1):14–16.

74. Khazin V, Kaufman Y, Zabeeda D, et al. (2004) Milrinone
and nitric oxide: combined effect on pulmonary artery pres-
sures after cardiopulmonary bypass in children. J Cardio-
thorac Vasc Anesth 18:156–159.

75. Barr FE, Tirona RG, Taylor MB, et al. (2007) Pharmacoki-
netics and safety of intravenously administered citrulline
in children undergoing congenital heart surgery: potential
therapy for postoperative pulmonary hypertension. J Tho-
rac Cardiovasc Surg 134:319–326.

76. Miller O, Tang S, Keech A, et al. (1995) Rebound pul-
monary hypertension on withdrawal from inhaled nitric
oxide. Lancet 346:51–52.

77. Chiodi H, Mohler J (1985) Effects of exposure of blood
hemoglobin to nitric oxide. Environ Res 37:355–363.

78. Koner O, Tekin S, Koner A, et al. (1999) Effects of phento-
lamine on tissue perfusion in pediatric cardiac surgery. J
Cardiothorac Vasc Anesth 13 (2):191–197.

79. Tweddell J, Hoffman G, Fedderly R, et al. (1999) Phenoxy-
benzamine improves systemic oxygen delivery after the
Norwood procedure. Ann Thorac Surg 67:161–167.

80. Hoffman GM, Tweddell JS, Ghanayem NS, et al. (2004) Al-
teration of the critical arteriovenous oxygen saturation rela-
tionship by sustained afterload reduction after the Norwood
procedure. J Thorac Cardiovasc Surg 127:738–745.

81. Buchhorn R, Bartmus D, Siekmeyer D, et al. (1998) Beta-
blocker therapy of severe congestive heart failure in infants
with left to right shunts. Am J Cardiol 81:1366–1368.

82. Consensus recommendation (1999) Consensus recommen-
dation for the management of chronic heart failure. On
behalf of the membership of the advisory council to im-
prove outcomes nationwide in heart failure. Am J Cardiol
83:1A.

83. Bristow M, Ginsberg R, Minobe W, et al. (1981) Decreased
catecholamine sensitivity and beta receptor density in fail-
ing human hearts. N Engl J Med 307:205–211.

84. Buchhorn R, Hulpke-Wette M, Russchewki W, et al. (2002)
Beta-receptor downregulation in congenital heart disease:
a risk factor for complications after surgical repair? Ann
Thorac Surg 73:610–613.

85. Bruns L, Chrisant M, Lamour J, et al. (2001) Carvedilol as
therapy in pediatric heart failure: an initial multicenter ex-
perience. J Pediatr 138:505–511.

86. Buchhorn R, Hulpke-Wette M, Hilgers R, et al. (2001) Pro-
pranolol treatment of congestive heart failure in infants with
congenital heart disease: the CHF-PRO-INFANT Trial. Int J
Cardiol 79:167–173.

87. Garson A, Gillette P, McNamara P (1981) Propranolol: the
preferred palliation for tetralogy of Fallot. Am J Cardiol
47:1098–1104.

88. Nussbaum J, Zane E, Thys D (1989) Esmolol infor the treat-
ment of hypercyanotic spells in infants with tetralogy of
Fallot. J Cardiothrac Anesth 3:200–202.

89. Wiest D, Garner S, Uber W, et al. (1997) Esmolol for the man-
agement of pediatric hypertension after cardiac operations.
J Thorac Cardiovasc Surg 115:890–897.

90. Follath F, Cleland J, Just H, et al. (2002) Efficacy and safety
of intravenous levosimendan compared with dobutamine
in severe low-output heart failure (the LIDO study): a ran-
domised double-blind trial. Lancet 360:196–202.

91. Nijhawan N, Nicolosi A, Montgomery M, et al. (1999)
Levosimendan enhances cardiac performance after car-
diopulmonary bypass: a prospective, randomized placebo-
controlled trial. J Cardiovasc Pharmacol 34:219–228.

92. Namachivayam P, Crossland DS, Butt WW, Shekerdemian
LS (2006) Early experience with Levosimendan in chil-
dren with ventricular dysfunction. Pediatr Crit Care Med
7:445–448.

93. Young J, Abraham W, Stevenson L, et al. (2000) Results of
the VMAC trial: vasodilation in the management of acute
congestive heart failure. Circulation 102:2794.

94. Mills R, LeJemtel T, Horton D, et al. (1999) Sustained hemo-
dynamic effects of nesiritide in heart failure: a randomized,

306

Page 673

Ind BLBK212-Andropoulos Trim: 216mm × 279mm October 29, 2009 18:11 Char Count=

Index

torsade de pointes, 323
total anomalous pulmonary venous return

(TAPVR), 388–91. See also left-to-right shunt
lesions; partial anomalous pulmonary
venous return (PAPVR)

anatomy, 388–90
anesthetic considerations, 391
anesthetic management, 392
pathophysiology/natural history, 390
postbypass echocardiographic data, 195t
surgical approaches, 390–91
types of, 388–90

tracheostomy, 6
tranexamic acid, 105, 106, 213
transcranial Doppler ultrasound, 173–4
transcutaneous external pacing, 334
transesophageal echocardiography (TEE), 183–98

in catheterization laboratory, 195–6
complications, 196–7
contraindications, 196
endocarditis prophylaxis, 197
equipment, 186
evaluation of congenital heart defects by, 191–3

assessment of pressure gradients, 193
assessment of ventricular filling/function, 193
preoperative evaluation, 191–3

history of, 184
imaging planes, 188–90

longitudinal plane examination, 189–90
multiplane examination, 189–90
transverse plane examination, 189

indications for, 185–6
influences on anesthetic/surgical management,

193–4
influences on clinical outcomes, 195
limitations of, 197–8
multiplane imaging, 184, 185f
and orotracheal intubation, 340
overview, 183
in positioning of central venous catheters, 147–8
probes, 186–91

insertion, 187–8
manipulation, 188–91
selection, 186–7

quality assurance, 198
role in VAD insertion, 620–21
sequential segmental analysis, 190–91
teaching/learning, 18
training/certification, 197–8
transgastric examination, 190

transgastric examination, 190
transitional atrioventricular canal, 382
transitional circulation, 46, 56f
transposition of great arteries (d-TGA), 444–50. See

also right-sided obstructive lesions
anatomy, 444–6
anesthetic considerations, 448–50
anesthetic management of, 452, 567–8
coronary artery anatomy, 445–6
with intact ventricular septum, 445
with left ventricular outflow tract obstruction,

445
options for surgical correction, 447–8
pathophysiology/natural history of, 446–7

prebypass echocardiographic data, 192t
preoperative evaluation, 270–71
terminology, 225
with ventricular septal defect, 445

transpulmonary thermodilution cardiac output,
159

transthoracic catheters, 146–7
transverse plane examination, 189
tribromethanol, 4
tricuspid atresia, anatomical features of, 457f
tricuspid valve, Ebstein’s malformation of, 47
triiodothyronine, 67, 248–9
troponin C, 58
troponin I, 58
troponin T, 58
truncus arteriosus, 386–8

anatomy, 386–7
anesthetic considerations, 387–8
anesthetic management, 392, 564
development of, 47
partitioning of bulbus cordis and, 43
pathophysiology/natural history, 387
postbypass echocardiographic data, 195t
prebypass echocardiographic data, 193t
preoperative evaluation, 276
types of, 386–7

tubing, 96–7
tumor necrosis factor-alpha (TNF-α), 123, 126
tunneled Broviac type percutaneous/intracardiac

lines, 147–9
Turner syndrome, 552t

ulnar artery, 153
ultrafiltration, 103–4

in cardiopulmonary bypass circuit, 96
conventional, 103–4, 130, 249
modified, 103–4, 130, 249
zero-balance ultrafiltration, 249

ultrasound, 155–6
umbilical arteries, 43–4, 152
umbilical veins, 41, 142–3
umbilical venous catheters (UVCs), 143
Univent tube, 345

valvotomy, 531
vancomycin, 549
vascular access and monitoring, 141–62

arterial access, 150–3
arterial cutdown, 153
axillary artery, 152
brachial artery, 152
dorsalis pedis artery, 153
femoral artery, 150–51
posterior tibial artery, 153
radial artery, 150
temporal artery, 152
ulnar artery, 153
umbilical artery, 152

complications, 159–62
arrhythmias, 162
infection, 161–2
malposition, 160–61
perforation, 160–61
pneumothorax, 161

systemic air embolus, 162
thrombosis, 159–60

percutaneous pulmonary artery catheterization,
153–4

ultrasound guidance, 155–6
venous access, 149–50

continuous SVC oxygen monitoring, 147
correct placement of central venous catheters,

147–9
direct transthoracic intracardiac vascular

access, 146–7
percutaneous central venous access,

143–6
percutaneously inserted central catheters,

149–50
peripheral veins, 141–2
tunneled Broviac type

percutaneous/intracardiac lines, 147
umbilical veins, 142–3

vascular monitoring, 156–9
cardiac output monitoring, 158–9
central venous oxygen saturation monitoring,

159
central venous waveforms, 158
intravascular pressure waveforms, 156–8
left atrial waveforms, 158
right atrial waveforms, 158

vascular rings, 480–82
anatomy, 480–81
anesthetic considerations/approaches, 482
management of, 489
pain control, 482
partial, 481
pathophysiology/natural history of, 481
postoperative airway management, 482
surgical approaches, 481–2

vascular tone, regulation of, 67
vasoactive drugs, 292t
vasoconstrictors, 296–7

norepinephrine, 296
phenylephrine, 296–7
vasopressin, 297

vasodilators, 297–300
inhaled nitric oxide, 299–300
nitroglycerin, 297
phenoxybenzamine, 300
phentolamine, 300
prostaglandins, 298–9
sildenafil, 299
sodium nitroprusside, 297–8

VATER association, 552t
vecuronium, 81, 89, 607
velocardiofacial syndrome, 228
venous access, 141–50. See also arterial access;

vascular access and monitoring
continuous SVC oxygen monitoring, 147
correct placement of central venous catheters,

147–9
direct transthoracic intracardiac vascular access,

146–7
percutaneous central venous access, 143–6
percutaneously inserted central catheters,

149–50
peripheral veins, 141–2

641

Page 674

Ind BLBK212-Andropoulos Trim: 216mm × 279mm October 29, 2009 18:11 Char Count=

Index

venous access (Contd.)
tunneled Broviac type

percutaneous/intracardiac lines, 147
umbilical veins, 142–3

venous system, defects of, 49
ventilation/perfusion (V/Q) matching, 343
ventricular arrhythmias. See also arrhythmias
ventricular assist devices (VADs),

616–20
Abiomed BVS 5000, 618
anesthesia/sedation/analgesia for insertion,

622–3
anticoagulation, 623
antifibrinolytic therapy, 623
Berlin Heart VAD, 618
centrifugal pumps, 616–17
EXCOR, 618
HeartMate II, 619
MEDOS HIA-VAD system, 618
MicroMed DeBakey VAD Child, 619–20
outcome/complications, 624
in pediatric patients, 599

platelet aggregation therapies, 623
Tandem Heart, 617–18
Thoratec VAD, 618–19
weaning from, 622
weaning from cardiopulmonary bypass to,

621–2
ventricular fibrillation, 326
ventricular inversion, 268
ventricular looping, 51
ventricular segment, 51
ventricular septal defect (VSD), 379–81, 436–9.

See also atrial septal defect (ASD);
left-to-right shunt lesions; right-sided
obstructive lesions

algorithm for decision-making, 437–9
anatomy, 436
anesthetic considerations, 381
anesthetic management, 392, 563
closure of, 534–5
development of, 43
pathophysiology/natural history of,

380, 436

perioperative anesthetic management,
437–9

prebypass echocardiographic data, 192t
surgical approaches, 380–81, 436–7
in teenaged/adult patients, 267
transcatheter closure, 381
transposition of great arteries with, 445
types of, 380

ventricular septation, 43
ventricular tachycardia (VT), 322–3
verapamil, 328t, 329
video-assisted thoracoscopic surgery (VATS), 344
vitelline arteries, 43–4
vitelline veins, 41
volatile agents, 77–80

warm cardiopulmonary bypass, 108–9
weave network, 58
Williams syndrome, 552t
Wolf-Parkinson-White syndrome, 320

zero-balance ultrafiltration, 249

642

Similer Documents